Semaglutide vs tirzepatide: a complete comparison

Semaglutide and tirzepatide are the two most effective weight management medications currently approved in the United States. They are not the same drug, they do not work the same way, and the difference between them is larger than most comparisons suggest.

Every trial figure on this page is a group average from a controlled study that included lifestyle intervention, attributed to its source. None of it predicts what will happen to you, and individual results varied substantially within every group.

Head to head

Mechanism

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases after you eat. It prompts insulin release when blood glucose is high, suppresses glucagon, slows how quickly your stomach empties, and acts on appetite regulation centers in the brain. Semaglutide mimics that hormone with a much longer duration of action, which is what makes once-weekly dosing possible.

Tirzepatide acts on two receptors, GIP and GLP-1. GIP, glucose-dependent insulinotropic polypeptide, is a second gut hormone in the same family. Tirzepatide is a single molecule that activates both.

Whether the added GIP activity is the reason tirzepatide produces larger average weight reductions in trials is still being characterized in the literature. The honest position is that the dual-agonist mechanism is associated with larger average reductions in the trial data, and that the precise contribution of GIP receptor activity in humans is an active research question rather than a settled one. Be skeptical of any source that explains the mechanism with more confidence than that.

Both are given as a once-weekly subcutaneous injection. Both are titrated slowly upward over months to limit gastrointestinal side effects. Both carry a boxed warning regarding thyroid C-cell tumors observed in rodent studies, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

The evidence

SURMOUNT-5 is the trial to cite, because it is the only randomized comparison at the approved weight management doses of both medications. Two limitations belong with it: it was open-label, meaning participants and investigators knew which drug was given, and it was not powered to compare rarer safety outcomes between the groups.

Do not line up two separate trials and subtract. Different trials enroll different populations, run for different durations and use different protocols. STEP 1 ran 68 weeks and SURMOUNT-1 ran 72. That is why the head-to-head matters more than any cross-trial arithmetic.

SURPASS-2 is routinely misread. It compared tirzepatide against semaglutide 1mg, the diabetes dose, not 2.4mg, the weight management dose. Anyone citing it as proof that tirzepatide beats semaglutide for weight loss is using a diabetes trial to answer a question it was not asked.

In adults who also have type 2 diabetes, both produce smaller average reductions. This pattern is well documented, and expectations set by the non-diabetes trials will not match.

The evidence

The side effect profiles are broadly similar, because both act on the same GLP-1 receptor and the gastrointestinal effects follow from that.

In SURMOUNT-5, gastrointestinal adverse events were common in both groups, and discontinuation because of adverse events was in the single digits and broadly similar between them. We describe that qualitatively rather than quoting a percentage, because the two arms are close enough that a rounded figure would imply a difference the trial was not designed to establish.

Two practical observations the trial tables do not capture. Side effects concentrate in the days after a dose increase, which is why titration exists and why slowing it down is a normal clinical response rather than a failure. And individual tolerance varies enormously, with no way to predict from trial data which molecule you personally will tolerate better. Some people who cannot tolerate one do fine on the other.

Report severe or persistent abdominal pain, persistent vomiting, or signs of an allergic reaction to a clinician immediately.

Choosing

There is no universally better molecule. There is a better fit for a given set of circumstances. Work through these, then take the answer into your intake rather than treating it as settled.

If your priority is the largest average reduction in the trial data. Tirzepatide produced larger mean reductions in the direct head-to-head comparison and in its own pivotal trial. If nothing else in your situation points the other way, that is the evidence-led starting point.

If you have established cardiovascular disease. Semaglutide has outcome data here that tirzepatide does not currently have in this population. The SELECT trial (Lincoff and colleagues, New England Journal of Medicine, 2023) studied semaglutide 2.4mg in adults with established cardiovascular disease and overweight or obesity, without diabetes, and reported a reduction in major adverse cardiovascular events against placebo. That is a meaningful distinction and it is also a coverage lever.

If you have moderate to severe obstructive sleep apnea. Tirzepatide has an approved indication in this population that semaglutide does not, which can change both the clinical rationale and the coverage conversation.

If you have type 2 diabetes. Both molecules have diabetes-approved products. Direct comparison in that population favored tirzepatide on glycemic control. This is a decision for whoever manages your diabetes.

If cost is your constraint. Semaglutide is generally the less expensive molecule. At Society, semaglutide plans start from $149 per month against $249 for tirzepatide. Those are starting prices rather than the whole answer, so ask what the plan you would actually be placed on costs.

If coverage is your constraint. Check which one your plan prefers before you choose. Pharmacy benefit managers designate preferred products, and the one your plan prefers may be far cheaper than the one it does not, regardless of which has better trial data. Society does not require insurance either way.

If you tried one and could not tolerate it. Trying the other is a normal clinical step. The side effect profiles overlap but individual tolerance genuinely differs.

If you are pregnant, planning pregnancy, or breastfeeding. Neither is appropriate. Speak to your clinician.

None of this replaces a clinical assessment. Your medical history, your other medications, your other conditions and your tolerance all factor in, and a prescriber weighs them together.

Switching

There is no dose equivalence between the two. 1mg of semaglutide is not equivalent to any particular dose of tirzepatide. They are different molecules with different potency profiles, and no conversion table exists.

You start tirzepatide at the beginning. Switching means starting at 2.5mg weekly and titrating from there, regardless of how high a semaglutide dose you were on. Starting higher to match your old dose is not how it works and increases the risk of significant gastrointestinal side effects.

Timing. Because both are weekly, the usual approach is to take the first tirzepatide dose on the day the next semaglutide dose would have been due. Your prescriber sets this.

Expect the side effects to return for a few weeks. You are starting a titration again, so the gastrointestinal effects you got past on semaglutide will likely reappear during the ramp-up, then settle.

Weight can move in either direction during the transition. Starting low after being at a maintenance dose of something else means a period at lower effective exposure. That is a normal part of the transition, not a sign the new medication is not working.

Switching in the other direction follows the same logic in reverse: start at 0.25mg of semaglutide and titrate up. Do not switch on your own. Dose changes and product changes are clinical decisions.

Questions

Society is a 100% online practice. A licensed US practitioner reviews your history, your other medications and your goals, and recommends what is appropriate for you rather than what you selected from a menu. The evaluation takes about two minutes and costs nothing, most members hear back within a day or two, and delivery is free, discreet and takes 1 to 2 days. Semaglutide from $149 per month, tirzepatide from $249 per month, no insurance required. You can pause, switch or cancel anytime, which stops future billing cycles, and the first two months of any treatment plan are non-refundable.

* Individual results may vary, and not all patients will qualify for treatment. Always consult a licensed healthcare provider before starting or modifying any medical treatment.

Society facilitates access to consultations with independent, licensed healthcare providers who evaluate each patient and determine eligibility for treatment. Prescription products require an online medical evaluation. Medications are prescribed by independent physicians and dispensed by licensed U.S. pharmacies or a patient's preferred pharmacy. Only a qualified healthcare provider can determine whether a treatment is appropriate for an individual's specific medical needs.
Providers are licensed in the state where the patient is located at the time of consultation, and availability may vary by state.
Society's services are intended for individuals 18 years of age or older. Age verification may be required as part of the intake process.
‍Society partners with licensed U.S. pharmacies. Certain treatments may include compounded medications, which are not FDA-approved and have not been evaluated by the Food and Drug Administration for safety, efficacy, or quality. Compounded medications may be prescribed by a healthcare provider based on individual patient needs or during periods of drug shortages. FDA-approved GLP-1 medications—such as Ozempic® (semaglutide), Wegovy® (semaglutide), and Zepbound® (tirzepatide)—are not compounded. Society is not affiliated with, endorsed by, or sponsored by the manufacturers of these products. All trademarks and brand names belong to their respective owners.
GLP-1–based treatments may carry risks, including the potential for thyroid C-cell tumors. These medications should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Please consult a healthcare provider for complete prescribing and safety information.
Prescription medications are dispensed only when determined appropriate by a licensed healthcare provider following an online medical evaluation. No prescription is guaranteed, and treatment decisions are made solely at the prescriber's clinical discretion.
Statements on this website have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Images shown are for illustrative purposes only; actual product appearance may vary.